PALISADE BIO, INC. — Director's Dealing 2021

Apr 29, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: PALISADE BIO, INC. (PALI)
CIK: 0001357459
Period of Report: 2021-04-27

Reporting Person: Finley John David (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-04-27	Common Stock	A	2396	—	Acquired	2396	Direct
2021-04-27	Common Stock	A	26322	—	Acquired	26322	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-04-27	Stock Option (Right to Buy)	$27.59	A	10418	Acquired	2025-06-12	Common Stock (10418)	Direct
2021-04-27	Stock Option (Right to Buy)	$27.59	A	9516	Acquired	2024-12-13	Common Stock (9516)	Direct
2021-04-27	Stock Option (Right to Buy)	$27.59	A	52068	Acquired	2027-11-10	Common Stock (52068)	Direct
2021-04-27	Stock Option (Right to Buy)	$41.20	A	14708	Acquired	2029-03-22	Common Stock (14708)	Direct
2021-04-27	Stock Option (Right to Buy)	$41.20	A	5662	Acquired	2029-03-22	Common Stock (5662)	Direct
2021-04-27	Stock Option (Right to Buy)	$41.20	A	19033	Acquired	2029-03-22	Common Stock (19033)	Direct
2021-04-27	Stock Option (Right to Buy)	$53.33	A	9702	Acquired	2029-03-22	Common Stock (9702)	Direct
2021-04-27	Stock Option (Right to Buy)	$26.85	A	7952	Acquired	2030-02-19	Common Stock (7952)	Direct
2021-04-27	Stock Option (Right to Buy)	$26.85	A	2595	Acquired	2031-04-26	Common Stock (2595)	Direct
2021-04-27	Warrant (Right to Buy)	$27.59	A	95	Acquired	2027-12-15	Common Stock (95)	Direct
2021-04-27	Warrant (Right to Buy)	$41.20	A	51	Acquired	2028-12-31	Common Stock (51)	Direct
2021-04-27	Warrant (Right to Buy)	$41.20	A	49	Acquired	2028-06-30	Common Stock (49)	Direct
2021-04-27	Warrant (Right to Buy)	$27.59	A	339	Acquired	2026-09-02	Common Stock (339)	Direct
2021-04-27	Warrant (Right to Buy)	$27.59	A	503	Acquired	2027-06-14	Common Stock (503)	Indirect
2021-04-27	Warrant (Right to Buy)	$27.59	A	40	Acquired	2028-01-01	Common Stock (40)	Indirect
2021-04-27	Warrant (Right to Buy)	$27.59	A	516	Acquired	2028-03-20	Common Stock (516)	Indirect
2021-04-27	Warrant (Right to Buy)	$27.59	A	27	Acquired	2028-04-16	Common Stock (27)	Indirect
2021-04-27	Warrant (Right to Buy)	$41.20	A	325	Acquired	2028-12-31	Common Stock (325)	Indirect
2021-04-27	Warrant (Right to Buy)	$41.20	A	293	Acquired	2028-06-30	Common Stock (293)	Indirect

Footnotes

F1: The Reporting Person acquired the shares of the Issuer in exchange for 88,182 shares of common stock of Leading BioSciences, Inc. ("LBS"), pursuant to the Agreement and Plan of Merger, dated December 16, 2020, among Seneca Biopharma Inc., Townsgate Acquisition Sub 1, Inc. and LBS (the "Merger"). Per the terms of the Merger, each share of LBS's common stock was converted into the right to receive 0.02719 shares of Seneca's common stock. In the Merger, the name of the Issuer was changed from Seneca Biopharma, Inc. to Palisade Bio, Inc.

F2: Received in the Merger in exchange for 968,098 shares of LBS common stock.

F3: The Reporting Person is the managing member of FCW Investments LLC and has sole investment and voting power over the securities held by this entity.

F4: The stock option is fully vested.

F5: Received in the Merger in exchange for a stock option to acquire 383,200 shares of LBS common stock for $0.75 per share.

F6: The stock option vested according to the following schedule: 58% of the shares underlying the option vested on the grant date and the remaining 62% vested in five equal quarterly installments thereafter beginning on December 12, 2016.

F7: Received in the Merger in exchange for a stock option to acquire 350,000 shares of LBS common stock for $0.75 per share.

F8: The stock option vests according to the following schedule: 31% of the shares underlying the option vested on the grant date and the remaining 69% vests in nine equal quarterly installments thereafter beginning on January 1, 2018.

F9: Received in the Merger in exchange for a stock option to acquire 1,915,000 shares of LBS common stock for $0.75 per share.

F10: The stock option vests according to the following schedule: 34% of the shares subject to the option vests on grant date and the remaining 66% vests in eight equal quarterly installments thereafter beginning on March 31, 2019.

F11: Received in the Merger in exchange for a stock option to acquire 541,000 shares of LBS common stock for $1.12 per share.

F12: The stock option vests in 12 equal quarterly installments from the vesting commencement date.

F13: Received in the Merger in exchange for a stock option to acquire 208,300 shares of LBS common stock for $1.12 per share.

F14: Received in the Merger in exchange for a stock option to acquire 700,000 shares of LBS common stock for $1.12 per share.

F15: The stock option vests according to the following schedule: 67% of the shares underlying the option vests on grant date and the remaining 33% vests in four equal quarterly installments thereafter beginning on March 31, 2020.

F16: Received in the Merger in exchange for a stock option to acquire 356,855 shares of LBS common stock for $1.45 per share.

F17: Received in the Merger in exchange for a stock option to acquire 292,500 shares of LBS common stock for $0.73 per share.

F18: Received in the Merger in exchange for a stock option to acquire 95,463 shares of LBS common stock for $0.73 per share.

F19: Received in the Merger in exchange for a warrant to purchase 3,500 shares of LBS common stock for $0.75 per share.

F20: Received in the Merger in exchange for a warrant to purchase 1,894 shares of LBS common stock for $1.12 per share.

F21: Received in the Merger in exchange for a warrant to purchase 1,824 shares of LBS common stock for $1.12 per share.

F22: Received in the Merger in exchange for a warrant to purchase 12,500 shares of LBS common stock for $0.75 per share.

F23: Received in the Merger in exchange for a warrant to purchase 18,500 shares of LBS common stock for $0.75 per share.

F24: Received in the Merger in exchange for a warrant to purchase 1,500 shares of LBS common stock for $0.75 per share.

F25: Received in the Merger in exchange for a warrant to purchase 19,000 shares of LBS common stock for $0.75 per share.

F26: Received in the Merger in exchange for a warrant to purchase 1,000 shares of LBS common stock for $0.75 per share.

F27: Received in the Merger in exchange for a warrant to purchase 11,994 shares of LBS common stock for $1.12 per share.

F28: Received in the Merger in exchange for a warrant to purchase 10,787 shares of LBS common stock for $1.12 per share.